Discontinued — last reported Q3 '25
Dow Intangibles (Net) decreased by 35.4% to $1.43B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 13.7%, from $1.65B to $1.43B. Over 5 years (FY 2020 to FY 2025), Intangibles (Net) shows a downward trend with a -8.0% CAGR.
High levels reflect significant investment in growth through acquisitions; changes indicate the impact of amortization or impairment charges.
This includes the value of acquired intellectual property, such as patents, trademarks, and drug licenses, net of accumu...
Very high in the pharmaceutical industry due to the reliance on patent-protected drug portfolios.
intangible_assets_net| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.09B | $2.96B | $2.86B | $2.74B | $2.60B | $2.47B | $36.00M | $2.34B | $2.23B | $2.13B | $2.09B | $1.97B | $1.88B | $1.84B | $1.97B | $1.65B | $1.61B | $1.55B | $2.21B | $1.43B |
| QoQ Change | — | -4.2% | -3.3% | -4.2% | -5.3% | -5.1% | -98.5% | >999% | -4.5% | -4.4% | -2.0% | -5.9% | -4.7% | -1.9% | +7.2% | -16.2% | -2.8% | -3.7% | +42.8% | -35.4% |
| YoY Change | — | — | — | — | -16.0% | -16.7% | -98.7% | -14.9% | -14.2% | -13.5% | >999% | -15.8% | -16.0% | -13.7% | -5.6% | -16.0% | -14.3% | -16.0% | +11.9% | -13.7% |